The FDA has warned Amylin Pharmaceuticals that they have made false and misleading statements about the diabetes drug Byetta.
The FDA letter was sent to Amylin Pharmaceuticals, alerting the company that federal regulators were aware of statements made by representatives that provided misleading or false information about the benefits of their product.
Download the FDA Warning Letter here.